REG - hVIVO PLC - Issue of Equity and Total Voting Rights

hVIVOAnnouncement

23/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260223:nRSW9910Ta&default-theme=true

RNS Number : 9910T  hVIVO PLC  23 February 2026

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Issue of Equity and Total Voting Rights

 

London, UK - 23 February 2026, hVIVO plc (AIM: HVO), a full-service early
phase Contract Research Organisation (CRO) and the world leader in human
challenge clinical trials, announces the issue of 1,386,991 new Ordinary
Shares of £0.001 each in the Company ("First Consideration Shares") to three
managers of Cryo-Store Limited ("Cryostore"). This issuance comprises the
first tranche (50%) of the equity consideration payable pursuant to the
acquisition of Cryostore announced on 27 February 2025
(https://polaris.brighterir.com/public/hvivo/news/rns/story/w9lzddw) (the
"Acquisition").

 

The remaining tranche of up to 1,386,991 new Ordinary Shares ("Second
Consideration Shares") will be issued on the second anniversary of the
Acquisition, subject to the individuals remaining in service of the Group.

 

Application has been made for the First Consideration Shares to be admitted to
trading on the AIM Market of the London Stock Exchange ("Admission"). It is
expected that Admission will become effective and trading will commence at
8.00am on 26 February 2026.

 

Total Voting Rights

 

Following admission, the Company will have 688,401,079 Ordinary Shares in
issue. This figure of 688,401,079 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information please contact:

 

 hVIVO plc                                                                           +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                                                      +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                                                            +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                                                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 ICR Healthcare (Financial PR & IR)                                                  hVIVO@icrhealthcare.com

 Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (Ticker: HVO) is full-service early phase
Contract Research Organisation (CRO) and the global leader in human challenge
trials. The company delivers end-to-end clinical development services to a
diverse and expanding client base, including seven of the world's ten largest
biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/) brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development Consulting
and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp (https://flucamp.com/) . Additionally, its five clinical sites support
outpatient Phase II and III trials, ensuring a seamless and efficient pathway
from discovery to late-stage development.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPPUAGPUPQPUP



            Copyright 2019 Regulatory News Service, all rights reserved